Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance
Background: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide and is primarily treated with radiation, surgery, and platinum-based drugs like cisplatin and carboplatin. The major challenge in the treatment of NSCLC patients is intrinsic or acquired resist...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
20 July 2018
|
| In: |
Genome medicine
Year: 2018, Volume: 10, Pages: 55 |
| ISSN: | 1756-994X |
| DOI: | 10.1186/s13073-018-0562-1 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s13073-018-0562-1
|
| Author Notes: | Sabrina Grasse, Matthias Lienhard, Steffen Frese, Martin Kerick, Anne Steinbach, Christina Grimm, Michelle Hussong, Jana Rolff, Michael Becker, Felix Dreher, Uwe Schirmer, Stefan Boerno, Anna Ramisch, Gunda Leschber, Bernd Timmermann, Christian Grohé, Heike Lüders, Martin Vingron, Iduna Fichtner, Sebastian Klein, Margarete Odenthal, Reinhard Büttner, Hans Lehrach, Holger Sültmann, Ralf Herwig and Michal R. Schweiger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1665667613 | ||
| 003 | DE-627 | ||
| 005 | 20230427160217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190515s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13073-018-0562-1 |2 doi | |
| 035 | |a (DE-627)1665667613 | ||
| 035 | |a (DE-599)KXP1665667613 | ||
| 035 | |a (OCoLC)1341212964 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Grasse, Sabrina |e VerfasserIn |0 (DE-588)1186150912 |0 (DE-627)1665668407 |4 aut | |
| 245 | 1 | 0 | |a Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance |c Sabrina Grasse, Matthias Lienhard, Steffen Frese, Martin Kerick, Anne Steinbach, Christina Grimm, Michelle Hussong, Jana Rolff, Michael Becker, Felix Dreher, Uwe Schirmer, Stefan Boerno, Anna Ramisch, Gunda Leschber, Bernd Timmermann, Christian Grohé, Heike Lüders, Martin Vingron, Iduna Fichtner, Sebastian Klein, Margarete Odenthal, Reinhard Büttner, Hans Lehrach, Holger Sültmann, Ralf Herwig and Michal R. Schweiger |
| 264 | 1 | |c 20 July 2018 | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.05.2019 | ||
| 520 | |a Background: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide and is primarily treated with radiation, surgery, and platinum-based drugs like cisplatin and carboplatin. The major challenge in the treatment of NSCLC patients is intrinsic or acquired resistance to chemotherapy. Molecular markers predicting the outcome of the patients are urgently needed. Methods: Here, we employed patient-derived xenografts (PDXs) to detect predictive methylation biomarkers for platin-based therapies. We used MeDIP-Seq to generate genome-wide DNA methylation profiles of 22 PDXs, their parental primary NSCLC, and their corresponding normal tissues and complemented the data with gene expression analyses of the same tissues. Candidate biomarkers were validated with quantitative methylation-specific PCRs (qMSP) in an independent cohort. Results: Comprehensive analyses revealed that differential methylation patterns are highly similar, enriched in PDXs and lung tumor-specific when comparing differences in methylation between PDXs versus primary NSCLC. We identified a set of 40 candidate regions with methylation correlated to carboplatin response and corresponding inverse gene expression pattern even before therapy. This analysis led to the identification of a promoter CpG island methylation of LDL receptor-related protein 12 (LRP12) associated with increased resistance to carboplatin. Validation in an independent patient cohort (n = 35) confirmed that LRP12 methylation status is predictive for therapeutic response of NSCLC patients to platin therapy with a sensitivity of 80% and a specificity of 84% (p < 0.01). Similarly, we find a shorter survival time for patients with LRP12 hypermethylation in the TCGA data set for NSCLC (lung adenocarcinoma). Conclusions: Using an epigenome-wide sequencing approach, we find differential methylation patterns from primary lung cancer and PDX-derived cancers to be very similar, albeit with a lower degree of differential methylation in primary tumors. We identify LRP12 DNA methylation as a powerful predictive marker for carboplatin resistance. These findings outline a platform for the identification of epigenetic therapy resistance biomarkers based on PDX NSCLC models. | ||
| 700 | 1 | |a Sültmann, Holger |d 1962- |e VerfasserIn |0 (DE-588)172777291 |0 (DE-627)697708144 |0 (DE-576)133633926 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genome medicine |d London : BioMed Central, 2009 |g 10(2018) Artikelnummer 55, 16 Seiten |h Online-Ressource |w (DE-627)594424275 |w (DE-600)2484394-5 |w (DE-576)304547956 |x 1756-994X |7 nnas |a Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance |
| 773 | 1 | 8 | |g volume:10 |g year:2018 |g pages:55 |g extent:16 |a Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13073-018-0562-1 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190515 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 172777291 |a Sültmann, Holger |m 172777291:Sültmann, Holger |d 50000 |e 50000PS172777291 |k 0/50000/ |p 24 | ||
| 999 | |a KXP-PPN1665667613 |e 3475870703 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"title":[{"title":"Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance","title_sort":"Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance"}],"name":{"displayForm":["Sabrina Grasse, Matthias Lienhard, Steffen Frese, Martin Kerick, Anne Steinbach, Christina Grimm, Michelle Hussong, Jana Rolff, Michael Becker, Felix Dreher, Uwe Schirmer, Stefan Boerno, Anna Ramisch, Gunda Leschber, Bernd Timmermann, Christian Grohé, Heike Lüders, Martin Vingron, Iduna Fichtner, Sebastian Klein, Margarete Odenthal, Reinhard Büttner, Hans Lehrach, Holger Sültmann, Ralf Herwig and Michal R. Schweiger"]},"note":["Gesehen am 15.05.2019"],"relHost":[{"title":[{"title":"Genome medicine","title_sort":"Genome medicine"}],"origin":[{"dateIssuedDisp":"2009-","publisher":"BioMed Central","dateIssuedKey":"2009","publisherPlace":"London"}],"pubHistory":["1.2009 -"],"disp":"Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistanceGenome medicine","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["594424275"],"zdb":["2484394-5"],"issn":["1756-994X"]},"language":["eng"],"part":{"extent":"16","pages":"55","volume":"10","text":"10(2018) Artikelnummer 55, 16 Seiten","year":"2018"},"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 28.09.2018"],"recId":"594424275"}],"person":[{"given":"Sabrina","family":"Grasse","role":"aut","display":"Grasse, Sabrina"},{"given":"Holger","family":"Sültmann","role":"aut","display":"Sültmann, Holger"}],"physDesc":[{"extent":"16 S."}],"id":{"eki":["1665667613"],"doi":["10.1186/s13073-018-0562-1"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"20 July 2018"}],"recId":"1665667613"} | ||
| SRT | |a GRASSESABREPIGENOMIC2020 | ||